MacroGenics stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

ECURE previously announced that the first patient dosed with ECUR-506 for OTC deficiency achieved a complete clinical ...

Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical ...

IGC Pharma has added HHS in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat agitation in ...

Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...

The US is set to withdraw from the WHO following Trump's disagreements regarding the agency's handling of the Covid-19 ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

MRT-6160 saw success in its safety and tolerability study while MRT-235 fell short in across a number of indications. Credit: Shutterstock / SergeiShimanovich. Monte Rosa Therapeutics has seen good ...

Of the 103 patients who completed the Phase III trial, more than half saw remission from a drug-induced condition.

NACE has collaborated with 17 Australian general practices and allergy clinics to launch the ARISE trial for young people with hay fever.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Flatiron Health has announced a partnership with NRG Oncology to implement the Flatiron Clinical Pipe in a multicentre NRG ...